Trial Profile
The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Anterior uveitis; Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2017 New trial record